Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Giotrif® efficacy and safety in elderly EGFRm+ NSCLC patients

12/04/2024  |  Author: Boehringer Ingelheim

Document ID: PC-MY-102594

Efficacy

RWDRI||Vietnam RWD 2024
RWDRI||Real-World First-Line GIOTRIF® for EGFRM+ NSCLC: Updated Survival Data from Korea
MYGIO2022COM||GIOTRIF® provides ≥3 years long-term response even with dose modification
MYBIONEGIO2022||South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
SEREAL||First-line GIOTRIF® data in over 30 real-world studies to-date
GIOTRIF® safety and effectiveness in the real world
Real-world evidence: GIOTRIF® in Japan
MYSEREAL||Real-world evidence: GIOTRIF® in Taiwan
Real-world evidence: GIOTRIF® in South Korea
SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
SEREAL||GIOTRIF® RWE in patients with brain metastases
SEREAL||Impact of GIOTRIF® in delaying CNS progression
SEREAL||GIOTRIF® RWE in Taiwan
SEREAL||GIOTRIF® efficacy in the real-world
SEREAL||GIOTRIF® in LUX-Lung 7
MYGIO2022COM||GIOTRIF® in elderly
MYBIONEGIO2022||GIOTRIF® in uncommon EGFR mutations
RWDRI||GIOTRIF® in Uncommon Mutation - A database analysis of >1000 NSCLC Patients

RELATED CONTENT